Skip to content

Tow Techniques of Adductor Canal Block for Analgesia After Total Knee Replacement

Ultrasound-guided Continuous Adductor Canal Block for Analgesia After Total Knee Replacement: Comparison of Block at the Entrance and Middle of the Canal

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03942133
Enrollment
62
Registered
2019-05-08
Start date
2019-05-11
Completion date
2019-12-16
Last updated
2020-01-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesia, Nerve Block, Total Knee Arthroplasty

Keywords

adductor canal block

Brief summary

This study compares the tow technique of continues adductor canal block for total knee replacement surgery. Half participants will receive catheterization at the entrance of the adductor canal, while the other half will receive catheterization at the middle point of the adductor canal.

Interventions

PROCEDUREultrasound-guided short-axis placement of catheter at the entrance of the adductor canal

Ultrasound probe is placed at the entrance of the adductor canal in short axis ,insertion of a PAJUNK Contiplex S catheter with the tip of the catheter located at the entrance of the canal

PROCEDUREultrasound-guided long-axis placement of catheter at the middle of the adductor canal

Ultrasound probe is placed at the middle of the adductor canal in long axis with the caphelad end of the probe aligned with the entrance of the canal. insertion of a PAJUNK Contiplex S catheter with the tip of the catheter located at the middle of the canal

Sponsors

Peking Union Medical College Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* 18-80 years * Knee-arthroscopy * Written consent * ASA I-III * BMI 19-35

Exclusion criteria

* Unable to communicate with the investigators (e.g., a language barrier or a neuropsychiatric disorder). * coagulopathy or on anticoagulant medication * Allergic reactions toward drugs used in the trial * History of substance abuse * Infection at injection site * Can not be mobilised to 5 meters of walk pre-surgery

Design outcomes

Primary

MeasureTime frame
cumulative sulfentanil consumption at 24 hours after surgery24 hours after surgery

Secondary

MeasureTime frameDescription
The pain scores at rest determined by the numeric rating scale (NRS, 0-10)at 0,2,4,8,24,48 hours postoperatively11-point numerical rating scale (NRS; 0, no pain; 10, maximum pain imaginable).
The pain scores on adduction of the keen determined by the numeric rating scale (NRS, 0-10)at 0,2,4,8,24,48 hours postoperatively11-point numerical rating scale (NRS; 0, no pain; 10, maximum pain imaginable).
incidence of postoperative nausea and vomiting (PONV)within 48 hours after surgery
the strength of quadriceps femoris0,2,4,8,24,48 hours postoperativelyQuadriceps strength was assessed on a 0-5 scale as per the Medical Research Council Scale quadriceps motor strength(0 = no voluntary contraction possible, 1 = muscle flicker, but no movement of limb, 2 = active movement only with gravity eliminated, 3 = movement against gravity but without resistance, 4 = movement possible against some resistance and 5 = normal motor strength against resistance)
complicationswithin 3days after surgeryRecord complications including catheter dislodgment, puncture point infection, leakage,falling down,et al.
cumulative sulfentanil consumption at other time points after surgery2,4,8,48 hours postoperatively
Patient satisfaction with anesthesiawithin 5th day after surgeryPatient satisfaction with anesthesia was assessed using a 5-point scale (5, very satisfied; 4, satisfied; 3, neither satisfied nor dissatisfied; 2, dissatisfied; 1, very dissatisfied)

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026